Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism

Archives of Neurology

Volumn 62, Issue 6, 2005, Pages 917-921

  Hauser, Michael A ^a,b,e   Li, Yi Ju ^a,b   Xu, Hong ^a,b   Noureddine, Maher A ^a,b   Shao, Yujun S ^a   Gullans, Steven R ^c   Scherzer, Clemens R ^c   Jensen, Roderick V ^c,d   McLaurin, Adam C ^a,b   Gibson, Jason R ^a,b   Scott, Burton L ^b   Jewett, Rita M ^a,b   Stenger, Judith E ^a   Schmechel, Donald E ^a   Hulette, Christine M ^a,b   Vance, Jeffery M ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

^d WESLEYAN UNIVERSITY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; UBIQUITIN;

ADULT; AGED; ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; FEMALE; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MALE; MITOCHONDRIAL GENETICS; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SUBSTANTIA NIGRA; UBIQUITINATION; COMPARATIVE STUDY; DEMENTIA; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; DEMENTIA; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARKINSON DISEASE; SUBSTANTIA NIGRA; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 20844436594     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.6.917     Document Type: Article

References (21)

1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
2. Scherzer CR, Jensen RV, Gullans SR, Feany MB. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. Hum Mol Genet. 2003;12:2457-2466.
3. Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or α-synuclein. Science. 2003;302:1769-1772.
4. Hauser MA, Li YJ, Takeuchi S, et al. Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. Hum Mol Genet. 2003;12:671-677.
5. Hardman CD, Halliday GM, McRitchie DA, Cartwright HR, Morris JG. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata. Exp Neurol. 1997;144:183-192.
6. Hulette CM, Pericak-Vance MA, Roses AD, et al. Neuropathological features of frontotemporal dementia and parkinsonism linked to chromosome 17q21-22 (FTDP-17): Duke Family 1684. J Neuropathol Exp Neurol. 1999;58:859-866.
7. Scott WK, Nance MA, Watts RL, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001;286:2239-2244.
8. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB international workshop. Neurology. 1996;47:1113-1124.
9. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol. 1996;55:97-105.
10. Cummings TJ, Strum JC, Yoon LW, Szymanski MH, Hulette CM. Recovery and expression of messenger RNA from postmortem human brain tissue. Mod Pathol. 2001;14:1157-1161.
11. Johnson SA, Morgan DG, Finch CE. Extensive postmortem stability of RNA from rat and human brain. J Neurosci Res. 1986;16:267-280.
12. Noureddine MA, Li Y-J, van der Walt JM, et al. Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra. Mov Disord. In press.
13. Li Y-J, Oliveira SA, Xu P, et al. Glutathione S-transferase omega-1 modifies ageat-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003;12:3259-3267.
14. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature. 2000;404:394-398.
15. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 2002;295:865-868.
16. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell. 2002;111:209-218.
17. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605-608.
18. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302:819-822.
19. Morel N, Dunant Y, Israel M. Neurotransmitter release through the V0 sector of V-ATPase. J Neurochem. 2001;79:485-488.
20. Hu K, Carroll J, Fedorovich S, Rickman C, Sukhodub A, Davletov B. Vesicular restriction of synaptobrevin suggests a role for calcium in membrane fusion. Nature. 2002;415:646-650.
21. Fernandez-Chacon R, Konigstorfer A, Gerber SH, et al. Synaptotagmin I functions as a calcium regulator of release probability. Nature. 2001;410:41-49.